Platelet collagen receptor gpvi-dimer recognizes fibrinogen and fibrin through their d-domains, contributing to platelet adhesion and activation during thrombus formation.
CONCLUSION: Only dimeric GPVI interacts with fibrinogen D-domain, at a site proximate to its collagen binding site, to support platelet adhesion/activation/aggregate formation on immobilized fibrinogen and polymerized fibrin. This article is protected by copyright. All rights reserved.
PMID: 29210180 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - December 5, 2017 Category: Hematology Authors: Induruwa I, Moroi M, Bonna A, Malcor JD, Howes JM, Warburton EA, Farndale RW, Jung SM Tags: J Thromb Haemost Source Type: research
Platelet collagen receptor gpvi ‐dimer recognizes fibrinogen and fibrin through their d‐domains, contributing to platelet adhesion and activation during thrombus formation
ConclusionOnly dimeric GPVI interacts with fibrinogen D‐domain, at a site proximate to its collagen binding site, to support platelet adhesion/activation/aggregate formation on immobilized fibrinogen and polymerized fibrin.This article is protected by copyright. All rights reserved. (Source: Journal of Thrombosis and Haemostasis)
Source: Journal of Thrombosis and Haemostasis - December 1, 2017 Category: Hematology Authors: Isuru Induruwa, Masaaki Moroi, Arkadiusz Bonna, Jean ‐Daniel Malcor, Joanna‐Marie Howes, Elizabeth A. Warburton, Richard W. Farndale, Stephanie M. Jung Tags: Original Article ‐ Platelets Source Type: research
An αIIbβ3 antagonist prevents thrombosis without causing Fc receptor γ‐chain IIa‐mediated thrombocytopenia
ConclusionsTMV‐7 shows antiplatelet and antithrombotic activities resulting from a mechanism different from that of all other tested αIIbβ3 antagonists, and may offer advantages as a therapeutic agent with a better safety profile. (Source: Journal of Thrombosis and Haemostasis)
Source: Journal of Thrombosis and Haemostasis - October 9, 2017 Category: Hematology Authors: Y. ‐J. Kuo, Y.‐R. Chen, C.‐C. Hsu, H.‐C. Peng, T.‐F. Huang Tags: Original Article Source Type: research
Timing of Angiography and Outcomes in High-Risk Patients with Non-ST Segment Elevation Myocardial Infarction Managed Invasively: Insights from the TAO Trial.
Conclusions -In patients with high-risk NSTEMI, undergoing CAG within the initial 12 hours after admission (as opposed to later, either 12 to 24 h or ≥24 h) was associated with lower risk of ischemic outcomes at 180 days.
PMID: 28893843 [PubMed - as supplied by publisher] (Source: Circulation)
Source: Circulation - September 11, 2017 Category: Cardiology Authors: Deharo P, Ducrocq G, Bode C, Cohen M, Cuisset T, Mehta S, Pollack CV, Wiviott SD, Elbez Y, Sabatine M, Steg PG Tags: Circulation Source Type: research
An αIIb β3 antagonist prevents thrombosis without causing FcγRIIa-mediated thrombocytopenia.
CONCLUSIONS: TMV-7 displays antiplatelet and antithrombotic activities by a mechanism different from all other tested αIIb β3 antagonists and may offer advantages as a therapeutic agent with a better safety profile. This article is protected by copyright. All rights reserved.
PMID: 28815933 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - August 16, 2017 Category: Hematology Authors: Kuo YJ, Chen YR, Hsu CC, Peng HC, Huang TF Tags: J Thromb Haemost Source Type: research
Successful Treatment of Pump Thrombosis with Tirofiban in the Setting of Acute Renal Insufficiency
Introduction: Left ventricular assist devices (LVAD) have become the standard of care for end stage cardiomyopathy, as destination therapy (DT) or bridge to transplant (BTT). Pump thrombosis is a potentially life threatening complication with incidence up to 13%. Guidelines recommend use of intravenous anticoagulation, thrombolytics, antiplatelet therapy, pump exchange or a combination thereof. Eptifibatide is renally excreted, therefore contraindicated in end stage renal disease, whereas tirofiban, due to high protein binding and 25% fecal elimination, can still be utilized. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - August 1, 2017 Category: Cardiology Authors: Khansa Ahmad, George Gavrilos, Tisha Suboc, Karen Meehan, Natalie Cora, Sunil Puawaa, Gregory Macaluso, Ambar Andrade, William Cotts Source Type: research
An αIIbβ3 antagonist prevents thrombosis without causing FcγRIIa‐mediated thrombocytopenia
ConclusionsTMV‐7 displays antiplatelet and antithrombotic activities by a mechanism different from all other tested αIIbβ3 antagonists and may offer advantages as a therapeutic agent with a better safety profile.This article is protected by copyright. All rights reserved. (Source: Journal of Thrombosis and Haemostasis)
Source: Journal of Thrombosis and Haemostasis - August 1, 2017 Category: Hematology Authors: Yu ‐Ju Kuo, Ying‐Ru Chen, Chun‐Chieh Hsu, Hui‐Chin Peng, Tur‐Fu Huang Tags: Original Article ‐ Platelets Source Type: research
E-022 Low dose eptifibatide for acute icad intervention results in high incidence of acute reocclusion
Conclusion
The low dose eptifibatide protocol employed here was safe in that no hemorrhages occurred. However, three of six target vessels re-occluded acutely. While the data are limited, the protocol appears to lack adequate potency to prevent re-occlusion of acutely treated ICAD lesions.
Disclosures
C. Roels: None. M. Brown: None. R. Janjua: None. D. Heck: 2; C; Stryker. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - July 23, 2017 Category: Neurosurgery Authors: Roels, C., Brown, M., Janjua, R., Heck, D. Tags: Electronic Poster Abstracts Source Type: research
E-021 Safety and efficacy of a low dose eptifibatide infusion during endovascular treatment of tandem occlusions
Conclusions
The low dose eptifibatide infusion resulted in a low incidence of SICH (5%) in the endovascular treatment of tandem intracranial occlusions. The infusion was not potent enough to maintain patency of the carotid artery in all patients. However, re-occlusion of the carotid artery was asymptomatic in the 4 patients where it occurred. This underscores that extracranial re-occlusion of the carotid artery is the lesser of evils compared with hemorrhagic stroke conversion. Limitations of the study include retrospective data collection, a low incidence of intravenous t-PA use, and lack of independent adjudication of an...
Source: Journal of NeuroInterventional Surgery - July 23, 2017 Category: Neurosurgery Authors: Roels, C., Brown, M., Janjua, R., Heck, D. Tags: Electronic Poster Abstracts Source Type: research
E-072 Use of eptifibatide as an alternative to preoperative standard dual antiplatelet therapy load for pipeline intracranial aneurysm flow diversion
Conclusion
Eptifibatide administration is a safe and effective alternative antiplatelet strategy to preoperative dual antiplatelet loading with clopidogrel and aspirin prior to intracranial aneurysm Pipeline flow diversion.
Disclosures:
A. Khan: None. R. Ryan: 2; C; Penumbra, Inc. A. Choulakian: None. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - July 23, 2017 Category: Neurosurgery Authors: Khan, , Ryan, R., Choulakian, A. Tags: Electronic Poster Abstracts Source Type: research
The Use of Eptifibatide Alone or in Combination With Heparin or Argatroban for Suspected Thrombosis in Patients With Left Ventricular Assist Devices
Abstract
Pump thrombosis and hemolysis in patients with left ventricular assist devices (LVADs) are associated with significant morbidity and mortality. Intensification of anticoagulation has been suggested as potential therapy, with mixed results. The aim of this study is to assess the safety and efficacy of adding eptifibatide with or without an anticoagulation agent in managing patients with LVAD presenting with hemolysis and suspected pump thrombosis. This retrospective single center study included all patients who presented with their first episode of suspected pump thrombosis and were treated with eptifibatide with o...
Source: Artificial Organs - June 16, 2017 Category: Transplant Surgery Authors: Abbas Bitar, Rajakrishnan Vijayakrishnan, Andrew Lenneman, Emma Birks, Todd Massey, Mark Slaughter, Dmitry Abramov Tags: Main Text Source Type: research
RP-HPLC method development and validation for determination of eptifibatide acetate in bulk ...
A new, rapid, economical and isocratic reverse phase high performance liquid chromatography (RP-HPLC) method was developed for the determination of eptifibatide acetate, a small synthetic antiplatelet peptide, in bulk drug substance and pharmaceutical dosage forms. The developed method was validated as per of ICH guidelines. The chromatographic separation was achieved isocratically on C18 column (150 x 4.60 mm i.d., 5µm particle size) at ambient temperature using acetonitrile (ACN), water and trifluoroacetic acid (TFA) as mobile phase at flow rate of 1 ml/min and UV detection at 275 nm. Eptifibatide acetate exhibited...
Source: Iranian Journal of Pharmaceutical Research - May 31, 2017 Category: Drugs & Pharmacology Source Type: research
Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: a systematic review and meta ‐analysis
(Source: Journal of Evidence-Based Medicine)
Source: Journal of Evidence-Based Medicine - April 27, 2017 Category: Journals (General) Authors: Xiaoqin Zhou, Xinyu Wu, Huan Sun, Jing Li Tags: ARTICLE Source Type: research
Intraoperative eptifibatide administration during urgent arterial bypass in neurosurgery – two case reports
(Source: World Neurosurgery)
Source: World Neurosurgery - April 20, 2017 Category: Neurosurgery Authors: Vasilije Stambolija, Goran Mrak, Marin Lozic, Josip Ljevak, Martina Miklic Bublic, Miroslav Scap Tags: Case Report Source Type: research
